| Dr Mitchell S Mckamey, DO | |
|
1400 29th St S, Great Falls, MT 59405-5315 | |
| (406) 454-2171 | |
| Not Available |
| Full Name | Dr Mitchell S Mckamey |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 17 Years |
| Location | 1400 29th St S, Great Falls, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831399864 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 12644 (Montana) | Primary |
| 207L00000X | Anesthesiology | 2011009252 (Missouri) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Great Falls Clinic Hospital | Great falls, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northstar Anesthesia Of Montana | 5395151294 | 11 |
News Archive
Soldiers in the National Guard with no history of alcohol abuse are at significant risk of developing alcohol-related problems during and after deployment, according to a new study published in Drug and Alcohol Dependence journal.
Researchers at the Burnham Institute for Medical Research (Burnham) may have found a new option for targeted breast cancer therapy by showing the link between a certain protein and the formation and development of blood vessels that feed breast tumors.
Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
› Verified 8 days ago
| Entity Name | Cmsc Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639109978 PECOS PAC ID: 5890602494 Enrollment ID: O20130502000527 |
News Archive
Soldiers in the National Guard with no history of alcohol abuse are at significant risk of developing alcohol-related problems during and after deployment, according to a new study published in Drug and Alcohol Dependence journal.
Researchers at the Burnham Institute for Medical Research (Burnham) may have found a new option for targeted breast cancer therapy by showing the link between a certain protein and the formation and development of blood vessels that feed breast tumors.
Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
› Verified 8 days ago
| Entity Name | Northstar Anesthesia Of Montana |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265059869 PECOS PAC ID: 5395151294 Enrollment ID: O20210301001196 |
News Archive
Soldiers in the National Guard with no history of alcohol abuse are at significant risk of developing alcohol-related problems during and after deployment, according to a new study published in Drug and Alcohol Dependence journal.
Researchers at the Burnham Institute for Medical Research (Burnham) may have found a new option for targeted breast cancer therapy by showing the link between a certain protein and the formation and development of blood vessels that feed breast tumors.
Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mitchell S Mckamey, DO Po Box 395, Ulm, MT 59485-0395 Ph: (406) 866-3165 | Dr Mitchell S Mckamey, DO 1400 29th St S, Great Falls, MT 59405-5315 Ph: (406) 454-2171 |
News Archive
Soldiers in the National Guard with no history of alcohol abuse are at significant risk of developing alcohol-related problems during and after deployment, according to a new study published in Drug and Alcohol Dependence journal.
Researchers at the Burnham Institute for Medical Research (Burnham) may have found a new option for targeted breast cancer therapy by showing the link between a certain protein and the formation and development of blood vessels that feed breast tumors.
Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
› Verified 8 days ago
Philip M. Vercio, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 401 15th Ave S, Ste. 109, Great Falls, MT 59405 Phone: 406-727-6311 Fax: 406-727-1070 | |
Craig Kenneth Sweeney, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3000 15th Ave S, Great Falls, MT 59405 Phone: 406-454-2171 | |
Michael E. Herbert, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 401 15th Ave S, Suite 109, Great Falls, MT 59405 Phone: 406-727-6311 Fax: 406-727-1070 | |
Dr. John Ethan Venditti, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1101 26th St S, Great Falls, MT 59405 Phone: 406-731-8888 Fax: 406-731-8876 | |
Erin Flaherty, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1900 32nd St S, Great Falls, MT 59405 Phone: 406-868-5589 | |
Dr. Joseph Eli Ghahari, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1101 26th St S, Great Falls, MT 59405 Phone: 406-731-8888 Fax: 406-731-8318 | |
Dr. Kathleen M Diller, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1101 26th St S, Great Falls, MT 59405 Phone: 406-731-8888 Fax: 406-731-8888 |